Compare Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 vs State Street SPDR S&P Biotech ETF — how do they compare? Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $64.59 (market cap $394.18M), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 25.6× Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 for 63 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SLVO | XBI | |
|---|---|---|
Market Cap | $394.18M | $10.11B |
Volume | 84,843 | 12,903,266 |
Sector | Income / Options Overlay | Broad Market / Factor |
52-Week High | $107.41 | $169.55 |
52-Week Low | $61.81 | $104.99 |
Typical Hold Time | 63 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLVO trades at $64.59, up 1.62% today but remains in a bearish technical trend, with moving averages signaling continued downward pressure. Financial ratios are not available, limiting fundamental clarity. Recent news highlights the stock crossing below its 50-day moving average and links its performance to silver price declines, indicating sensitivity to commodity markets.
The outlook is cautious due to bearish technicals and commodity volatility. Opportunities exist if silver prices stabilize, but risks include dollar strength and lack of fundamental data. Investors should weigh technical recovery potential against macroeconomic headwinds affecting silver.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
